

Feeding back of individual genomic results in Botswana: mapping opportunities and challenges

Mary Kasule (✉ marykasule@gmail.com)

Botswana-Baylor Children's Clinical Centre of Excellence

Mogomotsi Matshaba

Botswana-Baylor Children's Clinical Centre of Excellence

Ambroise Wonkam

University of Cape Town

Jantina de Vries

University of Cape Town

Research Article

Keywords: genomics, opportunities, challenges, regulatory oversight, actionability, resources, cost

Posted Date: May 5th, 2022

DOI: <https://doi.org/10.21203/rs.3.rs-1524983/v1>

License: © ⓘ This work is licensed under a Creative Commons Attribution 4.0 International License.

[Read Full License](#)

Additional Declarations: No competing interests reported.

Version of Record: A version of this preprint was published at BMC Medical Ethics on June 3rd, 2023. See the published version at <https://doi.org/10.1186/s12910-023-00912-1>.

Abstract

Purpose: We aimed to explore the views of stakeholders in Botswana involved in developing, implementing and applying ethical standards for return of individual study results from genomic research on feeding back individual genomic research results, thus mapping opportunities for and challenges regarding actionability requirements that could determine whether individual genomic research results should be fed back to participants.

Methods: Using in-depth interviews, we explored the views of sixteen (16) stakeholders involved in the conduct or regulation of genomic research in Botswana regarding what they thought were the opportunities for and challenges in feeding back individual genomic research results. We also deliberated on questions regarding whether the feedback of findings was necessary or not, whether only genomic results that have been verified in accredited diagnostic laboratories should be feedback and how important it is that participants who receive results have access to the interventions that would mediate the effects of the genomic findings. Coded data was analyzed through an iterative process of analytic induction to document and interpret themes.

Results: Overall, respondents were of the view that feedback of actionable individual genomic results was an important outcome that could benefit participants. However, a number of themes surfaced that pointed to opportunities for and challenges that exist in Botswana regarding requirements for feedback of actionable results that were mapped. Some of the opportunities cited by the respondents included the existence of good governance; democracy and humanitarianism; universal healthcare system; national commitment to science; research and innovation to transform Botswana into a knowledge-based economy; and applicable standard of care which could promote actionability. On the other hand, contextual issues like the prerequisite for return of only genomic research results that have been validated in accredited laboratories, the high cost of validation of genomic results, and linkage to care, as well as lack of experts like genomic scientists and counselors were considered as challenges for return of individual results.

Conclusion: We propose that decisions whether and which genomic results to return take into consideration contextual opportunities and challenges for actionability for return of results in a research setting. This is likely to avoid or minimize ethical issues of justice, equity and harm regarding actionability decisions.

Introduction

The quantity of genomic data generated about research participants in African populations by initiatives such as the Human, Health and Heredity in Africa (H3Africa) is exponentially increasing [1]. Since genomic research data provides information about all of a person's genes (the genome), including interactions of those genes with each other and with the person's environment, a deeper understanding of this data by the research fraternity could arguably benefit research participants when translated into

health care interventions [2]. This could translate into a strong argument to afford research participants the opportunity to receive at least some of their individual genomic findings. Yet few studies have analyzed what genomic research professionals in Botswana and Africa more broadly think about this issue and what they are doing to address it [3]. Therefore, questions about whether, which and how results ought to be fed back in genomics research have become an area of growing concern on the African continent. The emerging consensus from international [4] [5] as well as H3Africa guidelines [3] is that at least some findings in genomic research must be returned to individual donors if they wish, especially those that satisfy the standard actionability. “Actionability” pertains to the presence of an intervention to prevent, treat or improve the condition predicted or signalled by an incidental finding. However, this actionability only exists if the appropriate resources are available [3]. Yet there are unique considerations around actionability when genomics research takes place in lower or middle-income countries where healthcare systems may be severely under-resourced and where research participants are often unable to afford private healthcare. In those settings, what results are to count as actionable is variable and therefore not always clear.

In a publication by Ortiz-Osorno, [6], the authors developed the ‘Actionability at the Participant Research Setting Level’ (APRSL) model to describe the practical fluidity of the actionability requirements that determine whether individual genetic research results should be fed back. They argue that actionability varies from setting to setting, depending on the availability of resources. Therefore the setting should be the “driving force” in determining whether and what individual genomic results will be returned especially in the case of multi-site studies, where there may be wide variability in available medical resources as well as cultural diversity. This variation could be due to: (a) the availability of required resources; (b) the actual costs of those resources; (c) financial support available to participants; (d) the degree of referral programs and linkages to care; and (e) the level of expertise required and available in each study setting. These variations would be dependent on the opportunities for and challenges for availability of necessary resources in a setting. Whilst a valuable contribution to thinking about the return of individual genetic research results in international genomics research, the application of the APRSL model raises a number of questions in the African context. For instance, in African countries there may be considerable variation in what is available in urban areas vs rural areas in terms of health financing, cultures, health literacy, social-economic status and levels of education. To explore the usefulness of the APRSL approach, we critically interrogated the Botswana research setting where genomic research is still in its infancy in terms of technological advancement. This was done by interrogating the question relating to what professionals think about the opportunities for and challenges in feeding back individual genomic research results as well as whether research results need to be verified in a diagnostic laboratory, and how important it is that participants who receive results, have access to the interventions that would mediate the effects of the genomic finding.

Methods

Setting

Botswana is located at the center of Southern Africa positioned between South Africa, Namibia, Zambia and Zimbabwe. The country was one of the poorest countries at independence in 1966, but rapidly became one of the world's development success stories. Significant mineral wealth (diamonds), good governance, prudent economic management and a relatively small population of slightly more than 2 million have made it an upper middle-income country with a transformation agenda of becoming a high-income country by 2036 [7]. This has allowed the country to make strides in universal healthcare access for much of its population. The country has a Gross Domestic Product (GDP) average growth of 8%, mainly attributed to the mining sector, in particular the diamond industry, which accounts for 80% of export revenue. The country also boasts a GDP per capita of about \$16400 per year as of 2013 [8]. The total Health Expenditure as a percentage of the GDP is 5.4% [9]. Public sector healthcare services are almost free for citizens whilst non-citizens pay a subsidized fee. A nominal cost recovery system through a fee (5 Pula approximately 50 cents in US dollars) at the point of service applies in the public system, with exemption for vulnerable populations (children, pregnant mothers, the aged and communicable diseases of public health concern). However the extent to which these charges affect access has not been assessed [10]. The country also has private insurance in the form of medical aid schemes but only people in the higher-income brackets have access to this. These factors mean that Botswana citizens enjoy better living standards than those of lower middle income and low income economies [11]. Botswana is also characterised by a consultative culture of dialogue and humanitarianism, and a concept of "Botho" [12] which promotes solidarity and reciprocity. About 70% of Botswana's land is desert; therefore most of the population is concentrated in the south-eastern part of the country where the soil conditions are more favourable to arable production. This part also hosts the capital city Gaborone, where employment opportunities are higher. Most people in Botswana live in urban villages (43.0%) that are close to big cities while some live in rural villages (36.1%) and a few in cities and towns (20.9%) [13]. Of note, large biomedical research institutions are located in the cities and towns, while majority of the potential participants come from urban and rural villages. Due to a falling income from diamonds, Botswana is committed to transforming its economy from a resource economy into a knowledge-based economy through research, science, technology and innovation a mandate of the Ministry of Research, Science and Technology. The ministry has established parastatals like; the Botswana International University for Science and Technology (BIUST), Botswana Digital and Innovation Hub (BDIH), with one of its priorities being biotechnology in health to address cross cutting issues of health. BDIH established a Health Hub at the Ministry of Health and a Science and Technology Park that will comprise of some of the world's leading technology-driven and knowledge-based companies. In addition, Botswana has the Botswana Institute of Technology, Research and Innovation (BITRI) where genomic research is one of the strategic areas for development [14].

Despite the above successes, poverty and unemployment remain some of the major challenges facing the country. The unemployment rate is estimated at 18.1%. In addition, high rates of income inequality have led to an estimated 16.3% of the population living below the national poverty line [15]. Poverty is more prevalent in rural areas and among female-headed households especially among the youth and lowly-skilled people [16]. This situation is likely to have a bearing on feedback of actionable results as

income inequality affects affordability of treatment and prevention. Furthermore, levels of education and languages used to communicate information in genomic research can also impact on feedback of actionable results. Botswana's literacy rate stood at 90% in 2014, with greater literacy in towns and cities compared to rural areas [17]. Regarding languages spoken in Botswana, an estimated 70% of the population is ethno-linguistically homogenous and speaks Setswana which is the national language, although English is considered as the official language. The other 30% of the population speaks 28 other languages (Maruatona & Cervero, 2004). Therefore, education levels and languages used to communicate in research could have a huge bearing on the readability and comprehension of information provided to potential research participants through the informed consent process. Low education levels translate into low health and genomic literacy which would make the feedback of complex genomic results difficult to comprehend, impacting on decision making.

Being an upper-middle-income country, Botswana has a relatively strong healthcare system based on a primary healthcare model following the Alma Ata Declaration [18]. Overall, the Botswana Healthcare System is pluralistic with public, for profit, private non-profit and traditional medicine practice. The country provides free healthcare services through a Universal Health Care system that places emphasis on ensuring that its entire population receives the health services they need, without exposing them to financial hardship. Health financing in Botswana is dominated by the public sector (65%) with about 28% from the private sector. The country has developed a good network of infrastructure to support service delivery consisting of 265 primary care facilities, 101 of these with maternity beds, 343 health posts and 861 mobile clinic sites [10]. A significant 96% of urban residents live within a 5 km radius of the nearest Health Facility compared to 72% of rural residents [10]. However, the HIV pandemic (18%) [19] and its co-morbidities have over the years overstretched the health care system resources since the mid-1980s. Botswana has also invested a lot into laboratory infrastructure and Laboratory Quality Management Systems (QMS) required to promote excellence in laboratory services that support effective health care systems [20]. Currently, over 52 laboratories operate in Botswana, 8 of which are accredited with national certifications like the South African National Accreditation System (SANAS), Clinical Laboratory Improvement Amendments (CLIA), International Organization for Standardization (ISO) 15189 or the Southern African Development Community Accreditation Services (SADCAS) [21] [22]. The country has also established strong international research collaborations, with many US universities having a permanent presence in the country. These collaborations through northern partners, government ministries and parastatals, attract research funding, have attracted and trained a number of local highly qualified and experienced professionals in biomedical and socio-behavioural research including genomics, although more still needs to be done.

An established research governance and oversight system for research involving human subjects has existed since the 1980s. For example a mandatory requirement for a research permit before commencement of any research in the country is in place; country-wide Institutional Review Boards (IRBs) at academic and institutional level as well as Community Advisory Boards (CABs) mostly linked to IRBs have also been established. Routine training of IRB and CAB members both locally and internationally is also a requirement by the research regulations [23] [24]. However the capacity of IRB

members to review genomic research has not been assessed. With regard to policies, Botswana has a national health policy [25] that emphasizes research and development, health financing and health technologies among other things. National guidelines exist in form of Standard Operating procedures (SOPs), that guide the conduct of genetic research procedures, section:7.2 (iv). Although in terms of feedback of findings the SOPs have a provision which states that *“participants are informed during the consenting process that the researchers will endeavour to provide information about the outcome of the research, and when it is not intended to provide feedback”* [26], they lack detail on the conditions that determine the return of genomic results. Legally Botswana constitution provides for fundamental rights and freedoms of every individual [27] and a Data Protection Act No. 32 of 2018 (sec 23-26) [28]. All these oversight guidelines point to opportunities for feedback of individual results in Botswana.

Our study was hosted by Botswana-Baylor Children’s Clinical Centre of Excellence (BBCCE) which led a multi-county genomics Collaborative African Genomics Network (CAfGEN), an H3Africa genomic project conducted in Botswana, Eswatini and Uganda. The CAfGEN study aimed to identify host factors that are important to the progression of HIV and HIV-TB infection among children [29]. We explored the perspectives of stakeholders in Botswana involved in developing, implementing and applying ethical standards and policies for return of individual results on feeding back individual genomic research results, some of the responses from the in-depth interviews enabled mapping existing opportunities for and challenges in Botswana for developing guidelines or standard operating procedures for feedback of individual genomic results best practice.

Study population

Respondents included stakeholders from academia, research institutions and government ministries in Gaborone, the capital city of Botswana that are involved in developing, implementing and applying ethical standards and policies for biomedical and sociobehavioural research involving human subjects, including genomics research. These included healthcare providers, university lecturers, ethics committee members, community advisory board members, researchers and medical genetics professionals who had been involved in the conduct of or and regulation of research involving human subjects for at least two years.

Sampling, Data collection and analysis

Twenty seven (27) potential respondents were invited to participate in the study and sixteen (16) agreed to participate while nine (9) did not respond to our invitation and 2 could not honor their appointments. Data was collected by (MK) assisted by a research assistant (RW) both of whom are trained and experienced interviewers familiar with qualitative research methods. All participants were sent an invitation letter introducing them to the aims and objectives of the study as well as an Information Sheet. Each participant was also given a brief background of the researcher and the study prior to commencement of the interview. The interviews were conducted in English at the respondents’ workplaces, and lasted approximately 45 to 60 minutes. All interviews were audio-recorded with permission from the respondents and were later transcribed verbatim. Interviews were conducted until

saturation was reached [30], which we established through interim data analysis. No personal identifiers were collected, no master list was maintained that could link transcripts to respondents and audio recordings were assigned study identification codes. Established procedures for qualitative research methods were followed to ensure rigour and trustworthiness of data collection, coding and analysis procedures [31] [32] Briefly, transcripts were first checked for accuracy and familiarization with data. Thematic analysis was conducted by two of the authors (MK and JDV) and the interview texts were then analysed for content in line with the study aims. Guided by the objectives of the study, we initially open-coded selected transcripts to search for relevant concepts and a hierarchical coding scheme was used to identify the main study themes and sub-themes to generate a codebook. All transcripts were uploaded to and analysed in NVivo qualitative Version 12 (QSR) International Pty Ltd, 2012) software to aid in indexing, searching and retrieving sections of data. In-depth analysis of the coded data was conducted through an iterative process of analytic induction to document and interpret themes and patterns[33].

Results

Overall, all respondents supported the return of clinically important and actionable results. Generally, respondents were of the view that feedback of actionable individual genomic results was an important outcome that could benefit participants. However, a number of contextual themes surfaced that pointed both to opportunities for and challenges that exist in Botswana for feedback of individual genomic results. Some of the key opportunities noted by respondents included; Botswana's good governance; democracy and humanitarianism; free universal health care system; national commitment to science, research and innovation to transform Botswana into a knowledge-based economy; and applicable standard of care in that could create opportunities for actionability of results. However, some contextual issues like requirement for return of genomic results validated in an accredited laboratory, costs of validation and linkage to care as well as availability of experts in genomics research would pose challenges for feedback of actionable results.

Opportunities for return of individual genomic results

Botswana Health Care system

Our respondents were not so much concerned about whether or not participants could afford prevention and/ or follow-up treatment for validated conditions discovered from genomics research. This was attributed to the comparatively strong Health Care system which provides Universal Health Care supported by good governance, prudent economic management, democracy and humanitarianism which ensure that the values and principles of stewardship, transparency, participation, fairness, accountability and following the rule of law are adhered to. With this type of system, most respondents felt that despite the high costs of validation of results, follow-up treatment, and referrals, these would likely partly or fully be borne by government or private medical insurance. In this case cost may not be a barrier for actionability in Botswana. One respondent described this scenario as follows:

IDI 01: *“Our health system is a free kind of health system, or health for all in Botswana whereby everyone has got access. — Where something can be done the fact that our health system is— like this. We always pride ourselves, saying that health care is available to everyone; the facilities are within 5 kilometre radius for every settlement. You see, and you know that the referral is also there. The health care system is there with a wide coverage”.*

Some respondents however cautioned that although health services are free for all Botswana nationals, there are some inequity contextual challenges like low levels of education, low genomic literacy and poverty among the majority of research participants that can impact on actionability. These factors can affect comprehension of information feedback to participants, access to necessary genomic information as well as the cost of follow-up and care since the majority of participants may not be able to afford out-of-pocket services and lack of medical insurances. One respondent however noted that there could be solutions to these factors to enable return of actionable results. For example, empowering participants and communities through simple education that can be provided at the regular public meetings or community councils of Botswana villages referred to as “kgotla” meetings presided over by the village chief or headman. Here community issues are discussed to articulate people’s needs through dialogue. Village Development Committees (VDCs) are also available where such education can be provided mainly to promote transparency and trust as well as minimize stigma attached to some genetic diseases. This was expressed by one respondent as follows:

P04: Like majority of people I take care of at the hospital are poor people as they do not have private insurance! Many of them understand when/if you take time to explain things. They require a kind of education, so they can appreciate and understand what you are saying to them.

Some respondents felt that due to the high costs of treatment of most genomic conditions, results for such conditions should not be fed back because government might not afford. However, some were of the opinion that even such results should be fed back based on the existing cultural concept of “Botho” a Botswana concept of reciprocity and solidarity. Like one respondent commented:

IDI 03: *I think it's a very important point with regard to “nothing can be done” and it causes anxiety but let the participant decide. Again where is the line drawn? If nothing can be done, is that across board? What if I've got a cousin say for example in Germany where this technique is available and I can get myself there? Where is the line drawn? We have to be careful because then we're bringing in inequality of healthcare. Why should a person X not be told because we think they might not be able to act on the results? This might be a burden to them that still brings in that inequality, Humm— particularly – in terms of monetary management; — the money aspect also creates inequality—. So my fear is once we start doing that. We do run the risk of creating a very stratified society.*

In support of the above concept, another respondent said:

IDI 01: *“For some of the interventions it's not like really if you tell that old woman that you have cancer, who thinks that her kids can't pay? Who says? It is interesting in this country right now the things that you*

normally see. Some people can even bring donors on board to help so and so, to go and do this! I have seen some where we have pledged for people that you don't even know!"

Another opportunity noted for Botswana for return of individual results is the national commitment to science, research and innovation which will increase the quantity and volume of genomic data generated about research participants in Botswana populations. A deeper understanding of this data could arguably benefit research participants when translated into health care interventions. This could translate into a strong argument to afford research participants the opportunity to receive at least some of their individual findings. Due to this need, some of the responses seemed to suggest that there is a need for Botswana to prioritize genomic research since there is a lot that needs to be understood regarding genetic disease and if the results are shared with the participants, it would inform innovations as well as personal value to participants of understanding about their health conditions. Research investigators should take advantage of the infrastructure that government has developed at universities and parastatals which conduct genomic research. Emphasizing this point, one respondent said that:

IDI 09: "For Botswana there are a lot of opportunities, huge opportunities! They are things that we don't understand in our nation why they are different from other nations and the hypothesis is that they are driven by host genetics."

Applicable Standard of Care

The current regulations about the standard of care for research participants in Botswana are yet another opportunity for the return of individual genomic results. For example, the Botswana SOPs and Clinical Trials guidelines expect research investigators and sponsors to provide good standard of care or even better to participants during and after the research as a requirement for demonstrating equal respect for the dignity of research participants especially for multi-site studies. The regulations further elaborate that it is unacceptable for developed-country participants to be offered better standards of care than are offered to Botswana participants in a similar study. In this regard, some respondents felt that this could be a key determinant for determinant and basis for promotion of the return of individual findings as described below:

IDI 10: "Well, I don't know if it is very different from what's happening already. So, that in itself is not completely new and relates back to what we're feeding back and what is actionable within that setting. I don't think the government should change the way that they are rationing health care or deciding what they can and can't afford just based on what we can now test for."

Challenges

Availability of required resources

Although Botswana has a number of accredited laboratories, some of them might not be able to do genomic validation tests or if they can it is comparatively expensive. Therefore, most respondents expressed concern about the cost of validation of research results especially that of running and

maintaining the equipment, acquiring consumables and maintaining expert staff. In addition, the cost of sending samples abroad like to the United States or, more conveniently, South Africa is also high. Furthermore, lack of genetic health professionals such as medical geneticists and genetic counsellors was considered a problem. For our interviewees, these factors meant that outright promises of returning findings were a challenge as all these bring in a need for financial resources at government and individual level, as well as encourage collaborations to enable access to medical genetic services. Like one respondent said:

IDI 05: "I mean this confirmation has to be done in an accredited laboratory, which will be expensive. I see these as some of the challenges that confirmations are sometimes done outside the country or even the initial tests. Like here in Botswana, a lot of researchers say we have to send the samples somewhere because we don't have the capacity and even some of the tests are still being developed. How would you advise government to draft their policy in such a way that we can allow where possible if agreed to collaboration where it [validation] can be done outside. You know that processing a material transfer here is a big issue".

In the absence of accredited laboratories in the country that can perform genetic sequencing, one of the respondents supported and recommended return of findings which are from standard research methods or sensitive methods that have been used over time by laboratories in the country. However, the respondent emphasized that if the research tools are still under validation, such results would need further assessment so should not be feedback to participants. This suggestion was expressed as follows:

IDI 09: "For me, I think that if for example you are using processes that we call standard methods or standard diagnostic methods or sensitive methods that have been proven over time. I believe such results should be given back to participants. We should be on the benefit side of caution to say that we found a signal that needs to be validated. And then either the signal should be validated or at least there is some information that could be used for further improvement of patient care [—]. Hmm because then people can say Okay, based on this finding we think that it might reach actionable threshold, even though the methodology is not validated. I think the science is improving. Hmm and they are new tools coming up including genomic screening with tools that are still being researched. I think we should make the results available at minimum to the policymakers with further consultation with an Ethics body, medical ethics body, or maybe the participant".

Lack of experts in genomics research especially medical geneticists and genetic counsellors was also identified as a big obstacle to the return of individual findings in Botswana. However, considering the small population of Botswana, some respondents thought probably the best solution to this challenge would be to take advantage of the regional and international collaborative partnerships Botswana has established over the years, to attract these experts to build and or strengthen capacity in these areas. One of the respondents supported this suggestion by saying that:

P 04: Yeah! So the issue of costs is becoming global. For some of the things that involve cost, it is becoming evident that there is no need duplicating. Some of these Technologies can be shared in a cost-

effective way. So you find that within in southern Africa, for example, maybe you want in anatomic energies, microscopy or something specialized that costs millions and millions. It could be stationed in Botswana, but everyone around the region can access it”.

Research Regulatory oversight

Botswana has an old established governance and oversight framework for research involving human subjects that includes IRBs and CABs in most parts of the country; SOPs that include procedures on conduct of human genetic research. However; respondents noted that this framework has no guidelines specific to requirements for return of individual genomic results. They also noted lack of genomic research representation on IRBs. This is usually due to the fact that available experts in genomic research are also researchers so would be conflicted if they were to be appointed to serve as IRB members. One respondent expressed this concern proposed a solution as follows:

IDI 09: “We don't have systems, governance systems, ethical, legal or policies around these issues and we are waiting until we have an issue to deal with and then we ask ourselves. How do you deal is? But if people would realize that we are now in global village, yeah, there's no reason for us not to borrow vessels from elsewhere. Yes, there are International committees, International IRBs; we should be able to network with and say we have this submission. We are interested in getting external assessment”.

Discussion

The question of whether, how and to what extent genomic research results should be returned to research participants has become one of the most urgent and extensively debated ethical issues in genetics especially in developing world [34]. However, it is important to note that decisions to feedback findings in genomic research are impacted by, on the one hand a desire to respect participant autonomy by communicating as much information as possible, and on the other hand, a desire to protect participants against harm that may result from sharing poorly validated information [35]. Although the Botswana SOPs [26], section:7.2 (iv) requires that *“participants are informed during the consenting process that the researchers will endeavour to provide information about the outcome of the research, and when it is not intended to provide feedback”*, this requirement is not mandatory and is silent about which information should be disclosed, when and the criteria that determine the return of findings. According to the current international consensus, results that are feedback must have medical actionability [36]. However, actionability is linked to availability of resources in the genomic research setting that could be highly diverse, especially for multi-country studies or those implemented in regions of a country. Therefore, mapping opportunities for and challenges available in a research setting could be a form of assessing the research setting as recommended in the APSRL model as this can impact on medical actionability [6]. This has also been noted by other authors as important since opportunities and challenges may differ between research settings, in terms of available resources to act on the results (27).

Overall, respondents in our study were of the view that feedback of actionable individual genomic results was an important outcome that could benefit participants. This view is also supported by other studies

conducted in response to questions that have been raised in the past decades about the practice of not returning genetic test results and the current push for increased community and participant engagement across the research life-cycle [35] [37]. In this study a number of themes that could impact on return of actionable results surfaced that pointed both to opportunities for and challenges to the practice in Botswana. A good number of opportunities for return of individual result that exist in Botswana could support the possibility of returning individual results findings by research stakeholders. These opportunities can also offer hope to participants involved in genomic research in Botswana to receive at least some of their results, at least those that are actionable. The most important opportunity identified was the relatively strong health care system that exists in Botswana. This system is supported by good governance, democracy and a culture of humanitarianism, reciprocity and solidarity which cater for availability of most resources necessary for actionability. Strong Health Systems have been found to be lacking in many sub-Saharan countries [38]

Critical among the challenges identified was the strict requirement of feedback of only results validated in an accredited laboratory, a challenge for many sub-Saharan African countries. A survey conducted in forty-nine sub-Saharan countries showed that only 12 of these countries had laboratories that meet international standards. Most of these were located in South Africa (267) while Botswana had six, mostly used for research [39]. To circumvent the problem of diagnostic verification, one respondent proposed that results from robust experimental procedures could provide a useful alternative to facilitate feedback either at the national level or to individuals. This resonates with views from other authors [40]. National feedback would allow policy makers to plan for validation mechanisms either through establishing collaborative partnerships with settings that have accredited laboratories or develop a Quality Management System (QMS) for research laboratories testing human biospecimens [6]. With such a system in place, IRBs could permit the return of recommended results under the developed QMS. Alternatively, IRBs could also rely on laboratory analysis that is sufficient to provide confidence in the result, risk benefit analysis and availability of appropriate disclaimer information on the limitations of the validity and interpretation of the individual's result to permit the return of results. Furthermore, IRBs in Botswana need to develop specific guidelines for determination of return of individual genomic results as has been recommended elsewhere [6] [34] The cost of subsequent care, for those participants who receive actionable results has been a challenge in many research contexts[35]. From a clinical point of view Botswana has a well-established Universal Health Care system for all its citizens, although variability exists in urban versus rural settings as well as social economic status which can impact on the actionability of findings. The Botswana Integrated Health Services system enables linkage of patients to care both regionally and internationally. For example, cancer pathology-based diagnosis and treatment (chemotherapy and systemic surgery) are available at public facilities for free to citizens; radiotherapy is available at some hospitals for free for patients referred through the public facility system [41]. For high-risk variants where treatment is not available through the universal health care system, Botswana's cultural spirit of self-help, humaneness, solidarity and reciprocity that exist among families and communities compels them to pull together during times of need. This spirit of solidarity has been

extended to helping out family and community members seek care from within and outside the country through fundraising which gives hope to participants.

Respondents also raised concern about availability of genomic clinical expertise to confirm data quality, perform variant assessment to determine significance of results, and effectively communicate results to participants as has been mentioned elsewhere [42]. Lack of genomic counsellors was also viewed as critical by some respondents who felt that counselling was important for the delivery of comprehensive genomic medicine. The roles of genetic counsellors required for interpretation, explanation and feedback of genomic results, support of participants and their families in decision-making, calculation and prediction of risks of genetic disease and handling all the consequent psychosocial and ethical issues that may arise require specialized training [43]. Since in Botswana, genomic research is still in its infancy, there is need for capacity building in this area of expertise and it is hoped that with the country's commitment to developing capacity in genomic research, this problem could be solved in the near future. Also noted as a constraint was the lack of IRBs having representatives who are specialized in genomics on the local ethics committees. It was considered important for Botswana to set up Ad hoc committees with members specialized in genomics to review proposals submitted in this field. Other solutions to the challenges faced by local IRBs included the possibility of inviting expert genomics external reviewers from within or outside the country to review genomic research proposals, develop guidelines specific for appropriate and clear guidance of return of individual genomic results and at the same time develop local IRB capacity in genomic research through training.

Study Limitations

Genomic research in Botswana is in its infancy and the study was conducted in the capital city Gaborone with only a few research and academic institutions involved in genomic research; thus the small sample size. The sample size might not be large enough to sufficiently describe and address the research question at hand; hence these findings may not be generalized. Secondly, majority of our respondents had long experience in clinical and socio-behavioural research while others were long serving members of IRBs and Community Advisory Boards; were also health care providers, regulators and researchers which could have introduced some bias to the responses provided.

Conclusion

We describe opportunities for and challenges for the return of individual genomic results in Botswana regarding the availability of the necessary resources for actionability. Generalizing availability of resources across different settings could lead researchers to make false assumptions about what is (not) actionable. If actionability is one of the key criteria influencing decisions on what to feedback, then equally as such, the return of results should be proximally focused to the opportunities for and challenges that exist in a setting where the results emerge in order to guide actionability. Furthermore, as the contexts and policies for return of results continue to evolve; this will continue to create gaps between availability of resources to meet these requirements of those who have and those without, threatening international

collaboration. Therefore, we propose that decisions whether and which genomic results to return take into consideration prior mapping of contextual opportunities for and challenges for actionability requirements for return of results in a research setting. This is likely to avoid or minimize ethical issues of justice, equity and harm regarding actionability decisions.

Abbreviations

BBCCE: Botswana-Baylor Children's Clinical Centre of Excellence

BITRI: Botswana Institute of Technology, Research and Innovation

BIUST: Botswana International University for Science and Technology

CAfGEN: Collaborative African Genomics Network

CLIA: Clinical Laboratory Improvement Amendments

Gross Domestic Product (GDP)

H3Africa: Human, Health and Heredity in Africa

HIV: Human immunodeficiency virus

IRB: Institutional Review Board

ISO: International Organization for Standardization

Participant Research Setting Level' (APRSL)

QMS: Quality Management system

SOP: Standard Operating Procedure

SADCAS: Southern African Development Community Accreditation Services

SANAS: South African National Accreditation System (SANAS),

Declarations

Ethics approval and consent to participate

This study was reviewed and approved by the University of Botswana Research Ethics Committee (REF: UBR/RES/IRB/SOC/031), the Botswana Ministry of Health and Wellness Health Research Development Committee (REF: HPDME 13/18//10) and the University of Cape Town's (UCT) Faculty of Health Sciences Human Research Ethics Committee (HREC REF: 782/2017) prior to commencement of the study. All

participants provided signed informed consent for study participation. The study conformed to the WMA Declaration of Helsinki [26].

Consent for publication

Not Applicable

Availability of data and materials

The datasets used and/or analysed during the current study are available from the corresponding author on reasonable request using the email address provided.

Competing Interest

The authors declare that they have no competing interests.

Funding

This study was conducted as part of the IFGENERA study, which is funded by the NIH Common Fund H3Africa Initiative (NIH U54HG009790) to Prof Ambroise Wonkam and Prof Jantina de

Vries. The funders had no role in study design, data collection, and analysis, decision to publish, or preparation of the manuscript.

Authors' contributions

AW, and JDV conceptualized the project and designed the study; MK led the implementation of the Botswana study which involved identifying the potential participants, data collection and analysis; MK, JDV led the data interpretation and drafting the original manuscript; MM hosted the study and assisted with the logistics of data collection; All authors reviewed and approved the final version of the manuscript.

Acknowledgements

This work was supported by the National Human Genome Research Institute of the National Institutes of Health under Award Number U54HG009790 as part of the H3Africa Initiative. We appreciate the opportunity accorded by the Botswana-Baylor CAfGEN project funded by NIH grant 1U54AI110398 for hosting our study. We are also grateful to the H3Africa Consortium. We are extremely grateful to the participants and Ms Riley Moepswa who was the research assistant on this study.

References

1. Wonkam, A. and de Vries J. Returning incidental findings in African genomics research. *Nat Genet.* 2020;vol.52, no:17–20.

2. Fabsitz RR, McGuire A, Sharp RR, Puggal M, Beskow LM, Biesecker LG, et al. Ethical and Practical Guidelines for Reporting Genetic Research Results to Study Participants. *Circulation: Cardiovascular Genetics*. 2010;3:574–80.
3. Matimba A, de Vries J, Tindana P, Litter K, Nambaware V, Yakubu A, Stuart A S, Mc Curdy L, Sheely J, Marshall P, Rodriguez L and SJ. H3Africa guideline for the return of individual genetic research findings. Eleventh H3Africa Consortium meeting, Entebbe, Uganda. 2016;;1–14.
[http://h3africa.org/wp-content/uploads/%0A2018/05/H3Africa Feedback of Individual Genetic Results%0APolicy.pdf](http://h3africa.org/wp-content/uploads/%0A2018/05/H3Africa%20Feedback%20of%20Individual%20Genetic%20Results%0APolicy.pdf). Accessed 3 Apr 2022.
4. Williams JR. The 2016 CIOMS guidelines and public-health research ethics. *South African J Bioeth Law*. 10(2):93–5.
5. Bulletin of the World Health Organization. Declaration of Helsinki, ethical principles for scientific requirements and research protocols. 2013;79 (4):373.
6. Ortiz-osorno AB, Ehler LA, Brooks J. Considering Actionability at the Participant ' s Research Setting Level for Anticipatable Incidental Findings from Clinical Research. 2015;;619–32.
7. World Bank. The World Bank partners with the government to promote private sector led jobs, intensive growth, strengthen human and physical assets and support effective resource management. <https://www.worldbank.org/en/country/botswana/overview#1>. Accessed 3 Feb 2022.
8. Botswana Government. Report of the Auditor General on the accounts of the Botswana Government for financila year ended 31 March 2018. [https://www.gov.bw/sites/default/files/2020-03/Auditor General's report 2018-2019.pdf](https://www.gov.bw/sites/default/files/2020-03/Auditor%20General's%20report%202018-2019.pdf).
9. Health Policy Project. Health Financing Profile: Botswana. 2016.
https://www.healthpolicyproject.com/pubs/7887/Botswana_HFP.pdf.
10. Tapera R, Moseki S, January J. The status of health promotion in Botswana. *J Public Health Africa*. 2018.
11. Sebudubudu D. The impact of good governance on development and poverty in Africa: Botswana -A relatively successful African initiative. *African J Polit Sci Int Relations*. 2010;4:249–62.
<http://www.academicjournals.org/ajpsir>.
12. Morapedi S. Botho as a Way of Enhancing ProblemSolving in a Community Project: The case of Moshupa Study Group Project in Botswana. In: *Botswana Books and Records*. 2018. p. 50:178-88.
13. Statistics Botswana. Population and Housing Census 2011 Analytical Report. 2014.
14. National Human Genome Research Institute. Ministry of Tertiary Education, Research, Science and Technology. 2020. <https://www.genome.gov/about-genomics/fact-sheets/A-Brief-Guide-to-Genomics>. Accessed 26 Nov 2021.
15. Malema BW. Botswana's Greatest Challenge beyond the Successful Decline in Total Fertility Rate. *OALib*. 2020;07:1–15.
16. Botswana S. Botswana Core Welfare Indicator Survey. 2009.

17. Mpoeleng D. ICT Literacy Policy-Botswana. Proceedings of the 9th Session of the Intercontinental Council for the IFAP, May 30-31. 2016.
18. World Health Organization. Declaration of Alma-Ata. World Health Organization Regional Office for Europe. 1978.
19. Statistics Botswana. Botswana AIDS Impact Survey IV. 2013;:1–25.
http://www.cso.gov.bw/images/aids_summary.pdf.
20. Petti C, Peloge CR QT et. a. Laboratory Medicine in Africa: A barrier to effective health care. Clin Infect Dis. 2006;42(3):3773.
21. Southern Africa Development Community Accreditation Services. Southern African Development Community Accredited Laboratories. https://www.sadcas.org/accredited-organizations?field_organization_type_tid=11&title=&field_country_value=BW&field_accreditation_number_value=. Accessed 5 Feb 2022.
22. Ministry of Health B. Has Botswana Reached a “Tipping Point” in Laboratory Accreditation. [https://slmta.org/uploads/category_file/18/2.7 - Lab Accreditation Tipping Point \(Botswana\).pdf](https://slmta.org/uploads/category_file/18/2.7 - Lab Accreditation Tipping Point (Botswana).pdf). Accessed 3 Feb 2022.
23. Barchi F, Little MT. National ethics guidance in Sub-Saharan Africa on the collection and use of human biological specimens: A systematic review Ethics in Biomedical Research. BMC Med Ethics. 2016.
24. Barchi FH, Kasimatis-Singleton M, Kasule M, Khulumani P, Merz JF. Building research capacity in Botswana: A randomized trial comparing training methodologies in the Botswana ethics training initiative. BMC Med Educ. 2013;13.
25. Ministry of Health. National health policy: ‘Towards a Healthier Botswana’. 2011.
https://www.moh.gov.bw/Publications/policies/revised_National_Health_Policy.pdf. Accessed 3 Apr 2022.
26. Kasule M, Tubatsi G, Mashalla Y, Division D. Ministry of Health Standard Operating Procedures for Review of Biomedical and Bio-Behavioural Research in. 2011.
27. Parliament Government of Botswana. Constitution of Botswana.
<https://www.parliament.gov.bw/images/constitution.pdf>. Accessed 8 Feb 2022.
28. Parliament Government of Botswana. Data Protection Act No. 28 (section 23-26). Botswana: Botswana constitution; 2018.
<https://www.bocra.org.bw/sites/default/files/documents/DataProtectionAct.pdf>.
29. Mboowa G, Mwesigwa S, Katagirya E, Retshabile G, Mlotshwa BC, Williams L, et al. The Collaborative African Genomics Network (CAfGEN): Applying Genomic technologies to probe host factors important to the progression of HIV and HIV-tuberculosis infection in sub-Saharan Africa. AAS Open Res. 2018.
30. Creswell JW and Creswell JD. Research design: Qualitative, quantitative, and mixed methods approaches. Sage Publications; 2017.

31. Patton M.Q. Qualitative research and evaluation methods. Thousand Oaks. Cal.:Sage Publications; 2002.
32. Guba EG. Criteria for assessing the trustworthiness of naturalistic inquiries. *Educ Commun Technol.* 1981;29(2):75–91.
33. Kasule, M., Mogomotsi, M., Mwaka, E., Wonkam, A., de Vries J. Considerations of Autonomy in Guiding Decisions around the Feedback of Individual Genetic Research Results from Genomics Research: Expectations of and Preferences from Researchers in Botswana. *Glob Heal Epidemiol Genomics.* 2022;2022. doi:<https://doi.org/10.1155/2022/3245206>.
34. Wolf S.M. The past, present and future of the debate over return of research results and incidental findings. *Genet Med.* 2012;14:35–55.
35. National Academies of Sciences, Engineering and M. Returning individual research results to participants: guidance for a new research paradigm. 2018;93–140. <https://nap.nationalacademies.org/catalog/25094/returning-individual-research-results-to-participants-guidance-for-a-new>. Accessed 4 Apr 2022.
36. Bredenoord AL, Onland-Moret NC, Van Delden JJM. Feedback of individual genetic results to research participants: In favor of a qualified disclosure policy. *Hum Mutat.* 2011.
37. Middleton A, Morley KI, Bragin E, Firth HV, Hurles ME, Wright CF PM. Attitudes of nearly 7000 health professionals, genomic researchers and publics toward the return of incidental results from sequencing research. *Eur J Hum Genet.* 2016;24 (1):21–9.
38. Azevedo M. J. Historical Perspectives on the State of Health and Health System(s) in Africa: Challenges and Opportunities. Springer. 2017;1:1–73.
39. Schroeder LF, Amukele T. Medical Laboratories in Sub-Saharan Africa That Meet International Quality Standards. 2014;791–5.
40. Berwouts S, Morris MA DE. Approaches to quality management and accreditation in a genetic testing laboratory. *Eur J Hum Genet.* 2010;18 (1):S1-9.
41. Tapela NM, Peluso MJ, Kohler RE, Setlhako II. A Step Toward Timely Referral and Early Diagnosis of Cancer: Implementation and Impact on Knowledge of a Primary Care-Based Training Program in Botswana. 2018;8 May.
42. Thorogood A, Dalpé G, Knoppers BM. Return of individual genomic research results: are laws and policies keeping step? *Eur J Hum Genet.* 2019;27:535–46. doi:10.1038/s41431-018-0311-3.
43. Patch, C. and Middleton A. , Genetic counselling in the era of genomic medicine. *Br Med Bull.* 2018;126:27–36.